MarketCap
Facebook
X
TelegramQuarterly report 2024-Q4
added 05-07-2026
XTL Biopharmaceuticals Ltd. Operating Cash Flow 2011-2026 | XTLB
Annual Operating Cash Flow XTL Biopharmaceuticals Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.62 M | -707 K | -901 K | -1.05 M | -850 K | -908 K | -816 K | -1.12 M | -1.73 M | -1.86 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -707 K | -1.86 M | -1.16 M |
Quarterly Operating Cash Flow XTL Biopharmaceuticals Ltd.
| 2024-Q4 | 2024-Q3 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.62 M | - | -707 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -707 K | -1.62 M | -1.16 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-8.24 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-2.67 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.63 | -4.4 % | $ 191 M | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
14.6 B | - | - | $ 96.9 B |  Britain |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-10.4 M | $ 0.73 | -0.03 % | $ 33.4 M |  Israel |
 |
Arcturus Therapeutics Holdings
ARCT
|
-74.3 M | $ 7.83 | -5.21 % | $ 214 M | Israel |
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | USA |
 |
Esperion Therapeutics
ESPR
|
-13.1 M | $ 3.12 | - | $ 649 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-24.5 M | - | 0.74 % | $ 768 M | Israel |
 |
Exelixis
EXEL
|
884 M | $ 51.1 | -0.37 % | $ 13.9 B | USA |
|
Forte Biosciences
FBRX
|
-50.9 M | $ 23.96 | -2.84 % | $ 310 M | USA |
|
Galera Therapeutics
GRTX
|
-6.05 M | - | -32.59 % | $ 7.61 M | USA |
 |
Karyopharm Therapeutics
KPTI
|
-75.4 M | $ 8.9 | 0.56 % | $ 1.08 M | USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 4.4 | -7.76 % | $ 1.31 B | Canada |
 |
Midatech Pharma plc
MTP
|
-5.59 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
156 M | $ 17.3 | -5.57 % | $ 809 M | USA |
 |
BioNTech SE
BNTX
|
456 M | $ 91.99 | -0.26 % | $ 22.2 B | Germany |
 |
Compugen Ltd.
CGEN
|
31.6 M | $ 3.03 | 6.32 % | $ 283 M | Israel |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Gilead Sciences
GILD
|
10 B | $ 132.06 | -0.74 % | $ 164 B | USA |
 |
Genmab A/S
GMAB
|
7.77 B | $ 26.9 | 1.32 % | $ 1.74 B |  Danmark |
 |
Genprex
GNPX
|
-15.3 M | $ 0.86 | 1.2 % | $ 802 K | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.49 | -4.12 % | $ 5.75 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-8.47 M | - | 5.93 % | $ 314 M | Canada |
 |
Grifols, S.A.
GRFS
|
902 M | $ 7.79 | 1.04 % | $ 5.29 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Fortress Biotech
FBIO
|
-65.8 M | $ 2.3 | 3.14 % | $ 64.2 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 21.57 | -0.55 % | $ 2.74 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-12.5 M | $ 9.24 | 36.48 % | $ 264 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |